OvaScience Provides Update On Pipeline Advancements And Commercial Plans; New Potential Fertility Treatment Ovaprime? To Launch In 2015
Published: Jan 13, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, today provided an update on its product pipeline and commercial plans, which are based on its egg precursor cell (EggPCSM) technology platform. OvaScience expects to commercialize AUGMENTSM in international in vitro fertilization (IVF) clinics in 2014 and to launch its newest potential fertility treatment, OvaPrimeSM, in 2015.
Help employers find you! Check out all the jobs and post your resume.